Tularemia Companies

Latest Tularemia Companies Updates:

Jan 2024

Novavax,Leading the development of a next-generation tularemia vaccine candidate, NVX-CoV-2373, currently in Phase I clinical trials. This vaccine utilizes the same recombinant protein technology used in their COVID-19 vaccine, potentially offering longer-lasting protection against tularemia.Collaborated with government agencies and research institutions to accelerate the development and licensing of their tularemia vaccine candidate.

Bastille BioScience LLC Received FDA orphan drug designation for their investigational antibiotic, Tularomycin, specifically targeting tularemia treatment. This designation offers potential expedited development and marketing benefits.Conducted Phase II clinical trials evaluating the efficacy and safety of Tularomycin for treating human tularemia, with promising preliminary results.

Abbott Laboratories Introduced a new rapid diagnostic test for tularemia, ID NOW™ Tularemia, providing healthcare professionals with faster and more reliable detection at the point-of-care, critical for prompt treatment and outbreak control.Invested in research and development efforts to discover new antibiotics and therapeutic strategies for tularemia, addressing the limited treatment options currently available.

Centers for Disease Control and Prevention Launched a nationwide tularemia awareness campaign targeted at healthcare professionals, hunters, and outdoor enthusiasts in high-risk areas.Developed new diagnostic and outbreak response protocols for more efficient tularemia management and prevention of human cases.

List of Tularemia Key companies in the market:

• Nicholas Piramal


• Alkem


• GlaxoSmithKline


• Bayer AG


• Ranbaxy Laboratories


• Cipla Inc.


• Zydus Cadila


• Dr. Reddy's Laboratories


• Glenmark Pharmaceuticals


• Lupin Limited


• Pfizer Inc.